巴西聖保羅2026年5月12日 /美通社/ -- 5月6日，中興通訊在巴西聖保羅成功舉辦第五屆「智慧寬帶 變現未來」寬帶用戶大會。從安第斯山麓的哥倫比亞，到北美樞紐墨西哥，再到南美第一大市場巴西，中興通訊持續探索拉美寬帶經營新路徑。本次大會匯聚巴西及拉美地區300餘家主流運營商、ISP、行業專家與生態夥伴，巴西本地政府及行業協會等諸多領袖亦應邀出席。大會以寬帶網絡降本增效、家庭業務創新為雙引擎，依托系列智能寬帶變現解決方案，精準適配拉美細分市場及場景需求，助力運營商與ISP突破傳統管道經營模式，拉升基礎網絡ARPU、拓寬增收路徑、重塑行業核心競爭力。

中興通訊高級副總裁方暉在開幕致辭中表示，公司深耕拉美二十餘年，落地數百個標桿通信項目，網絡服務覆蓋巴西超1億用戶，深度扎根區域數字基礎設施建設。面向未來，中興通訊將持續以技術創新打造極致網絡體驗，以生態共贏釋放產業增長動能，以AI賦能全產業鏈升級；憑借「連接+算力」全棧能力，構建開放共生的智能數字生態，攜手拉美合作夥伴共創產業全新價值。

大會現場，中興通訊面向運營商及ISP市場，展示全新網絡經營理念與創新產品解決方案，將「智慧寬帶 變現未來」戰略構想轉化為可落地、可盈利的商業實踐。

面向運營商寬帶網絡建設，中興通訊始終致力於為每一位客戶打造「最好的寬帶網絡」。

在光接入領域， FTTx變現方案通過輕量化OLT降低建網門檻、CEM+AI實現精細化質差分析與精準營銷、AI全光園區與AI智會屏等創新拓展To B藍海市場，兼顧成本效率與ARPU提升，持續挖掘網絡增量價值。端到端智能ODN系統則為全生命週期網絡提供有力保障。

在承載網領域， C+L全頻一體化1.6T OTN方案，融合AI技術，憑借單波速率升級、極致頻譜利用率與智能化運維能力，攻克光網擴容成本高、服務響應慢等行業難題。同時，單槽28.8Tbps核心路由器與高性能100GE/400GE接入匯聚路由器，疊加AI流量智能調優、AI安全防護、AI動態節能功能，助力運營商搭建超寬、綠色、安全、智能的新一代IP網絡。

在智能運維側，AIOps智能運維平台大幅提升故障診斷效率，顯著削減全網OPEX，助力運維體系向L4級高階自智網絡穩步演進。

面向家庭寬帶網絡建設，中興通訊憑借「硬核技術實力及持續的AI技術創新」，以質量保障為支點、智能管控為優勢、長期演進為方向，為客戶提供更優的TCO保障。

在智能連接領域，以AI Wi-Fi 7為核心，充分發揮規格、覆蓋、管控、軟硬件及供應鏈等多重優勢，助力運營商精準選型與TCO持續優化。結合定制化套餐策略，幫助運營商擺脫價格戰，構建差異化競爭力。

在智慧家庭增值業務方面，以大模型能力為基座，聚焦AI運維、AI攝像頭、AI中屏三大核心抓手，打造集智管智控、健身娛樂、隨心看家於一體的家庭新體驗，推動家庭業務從基礎連接向高價值服務升級。

在智能運營方面，SCP平台實現全類型家庭設備統一納管、遠程診斷運維、一鍵網絡優化、被盜設備鎖定及基於多樣化報表的增值業務定向營銷，全業務一站式捆綁，降低運維成本、穩定提升收益，助力運營商構建高效運營體系，實現可持續價值變現。

針對ISP市場，中興通訊以「輕量建網、融合提效」破局，賦能增收。

輕量化PON方案實現快速、高性價比網絡部署，顯著縮短上市時間，幫助ISP搶佔市場先機。

Light OTN方案採用12.8T@2U高集成度設計+WebGUI極簡管理，支持單波1.6T傳輸及「零部署、上電即開通」，顯著降低光網絡部署成本與運維複雜度。

Light IP Network打通從CPE到接入、匯聚、骨幹的端到端輕量化IP融合方案，以統一開放架構、平滑演進產品、極簡智能運維為三大支柱，助力ISP實現異構網絡融合與持續運營。

在上述場景化方案之外，本次大會還迎來了三大亮點合作的集中呈現：中興通訊推出新一代TV 3.0機頂盒，標誌著巴西數字電視升級邁入關鍵階段；中興通訊攜手聯發科推出面向高端家庭與中小商業場景的Wi-Fi 7與萬兆光網絡解決方案，助力運營商挖掘高價值用戶；高通與中興通訊攜手打造面向 AI 時代的新一代網絡基礎設施，整合了高通原生 AI Wi-Fi、固定無線接入（FWA）平台技術，以及中興通訊在接入與網絡解決方案領域的技術領先優勢。

中興通訊副總裁、巴西代表處總經理呂茂亮表示，巴西是公司全球核心戰略市場。深耕拉美25年，中興通訊累計服務超100家運營商與ISP，鋪設光纖超6萬公里，覆蓋超3000萬家庭用戶。他指出，本次大會正是對本地客戶需求的精準回應：不止輸出領先技術與產品，更聚焦助力客戶實現商業成功。

面向未來，中興通訊將持續以「智慧寬帶變現未來」為指引，深耕巴西及拉美市場，依托「連接+算力」全棧技術能力，攜手本地運營商與生態夥伴，推動智能寬帶從建網覆蓋走向價值經營，助力區域通信產業實現高質量、可持續增長，共繪巴西數字經濟發展新藍圖。

媒體垂詢：
中興通訊
傳播部
電子郵件：[email protected]  

SHENZHEN, China, May 12, 2026 /PRNewswire/ -- TCL, a leading global technology company, announced its inclusion in Forbes' 2025 list of the World's Top Companies for Women, recognizing its success in building an inclusive culture and championing women in the workplace.

To compile the list, Forbes partnered with market research firm Statista to survey approximately 120,000 women working for multinational corporations in more than 36 countries. Each company's score aggregates survey responses with a "public opinion score" that quantifies women's gender perceptions of different companies, as well as data on women in executive and board positions. The list ranks 400 corporations with a significant global presence across at least two continents.

In addition to career advancement, TCL offers family-friendly benefits such as mother and baby rooms, extended paid maternity leave and childbirth allowances, along with women's healthcare services including cancer screening and psychological counseling.

"Women's empowerment is a core component of TCL's globalization and sustainability strategy, linking our technological innovation with social development," said Wei Xue, Vice President & Chief of the ESG Office at TCL Technology Group Corporation, and Chairperson of TCL Charity Foundation. "Our inclusion on Forbes' list is a tribute to TCL's long-term commitment to empowering women in the workplace and supporting their career development. We are honored to be included and proud of our track record of creating opportunity for all people."

TCL operates in more than 160 countries and regions, engaging with local communities and respecting local cultural norms to empower women in the workplace. The company maintains its commitment to diversity and inclusion by assessing Environmental, Social and Governance indicators in its global subsidiaries and using this data to inform its employment policies.

TCL Extends Female Empowerment Mission Beyond the Workplace

Since 2018, TCL has partnered with FIBA, the world's governing body for basketball, to promote female participation in the sport. The company has supported numerous global events and will continue its involvement with the upcoming FIBA Women's World Cup in Germany in September and the 2027 FIBA World Cup in Qatar. 

Through the Huameng Foundation, a philanthropic initiative established by TCL's founders, the company funds female-focused programs that have enabled nearly 1,000 young women from underprivileged families to complete high school and tertiary studies. The Foundation uses technology to advance its charitable causes, supporting community development in China and elsewhere.

In addition, TCL's dynamic and long-running #TCLforHer campaign leverages technology, sports and education to empower young women and nurture their ambitions through a variety of community initiatives. The campaign shares stories of trailblazers who challenge assumptions and tear down boundaries, inspiring women everywhere to boldly defy stereotypes and fulfill their potential. 

#TCLforHer has received numerous international marketing honors for its storytelling prowess. In January 2025, it won a prestigious Silver Telly Award—a major prize in the global documentary and TV brand film sector—for its 2024 marketing campaign, which centers around two brand films produced by a predominantly female team. 

TCL's inclusion on the Forbes list of the World's Top Companies for Women marks an important milestone, affirming the company's leadership in female empowerment and commitment to breaking the glass ceiling for women worldwide.

About TCL

Founded in 1981, TCL—short for "The Creative Life"—embodies creativity in every aspect of life. As a leading technology brand, TCL is dedicated to delivering innovative solutions—including TVs, smartphones, audio products, smart home devices, display technologies, and clean energy—that enhance customer experiences through two independent entities—TCL Industries and TCL Technology.

With 47 R&D centers and 40 manufacturing bases globally, TCL operates in over 160 countries and regions, cementing its position as a globally competitive smart technology brand. To further inspire greatness, TCL has become an official Worldwide Olympic and Paralympic Partner in the Home Audiovisual Equipment and Home Appliances category.

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide

Agreements include 13 programs with the potential to address significant unmet patient needs and support long‑term growth

SHANGHAI and PRINCETON, N.J., May 12, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui") (600276.SH; 01276.HK) and Bristol Myers Squibb ("BMS") today announced the companies have entered into global strategic collaboration and license agreements to advance a portfolio of 13 early stage programs in oncology, hematology and immunology, with the goal of accelerating discovery and development of innovative medicines for the benefit of patients worldwide.

The agreements include four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five innovative assets to be jointly discovered and developed by both companies, leveraging Hengrui's discovery engine and platform technologies across several innovative modalities. Hengrui has the option to co-develop select assets and the potential to conduct certain commercialization activities globally with BMS.

Under the collaboration, BMS obtains exclusive worldwide rights to the Hengrui‑originated assets outside Chinese mainland, Hong Kong SAR, and Macau SAR (the "Hengrui Territory"), while Hengrui obtains exclusive rights to the BMS‑originated assets within the Hengrui Territory, with BMS retaining rights for the rest of the world. Hengrui will be fully responsible for early clinical development to accelerate clinical proof of concept for these programs.

Aligned with the collaborative innovation strategies of both BMS and Hengrui, these agreements reflect the companies' continued focus on advancing innovative science through partnership in areas of significant unmet medical need. The collaboration brings together BMS's differentiated research and discovery strengths, global clinical development capabilities, regulatory expertise, and commercial scale with Hengrui Pharma's discovery engine, platform technologies, and efficient early-stage development expertise, enabling the advancement of a broad portfolio of high-value programs.

"This broad strategic collaboration reflects a highly synergistic collaboration between two global innovators with complementary strengths. By leveraging Hengrui's growing R&D capabilities and proven efficiency in discovering and advancing innovative therapies, we are poised to advance the best of both pipelines," said Frank Jiang, MD, PhD, Executive Vice President and Chief Strategy Officer of Hengrui Pharma. "It also reflects Hengrui's continued commitment to strengthen our global presence. Together, we aim to deliver meaningful benefits to patients worldwide."

"This strategic collaboration reflects our commitment to advancing innovative science while maintaining a disciplined approach to portfolio management," said Robert Plenge, MD, PhD, Executive Vice President and Chief Research Officer, Bristol Myers Squibb. "By leveraging complementary capabilities across geographies, we aim to accelerate early clinical learning and make informed decisions that support driving top tier growth in the next decade and, ultimately, our mission to deliver medicines that help patients prevail over serious diseases."

Under the terms of the agreement, BMS will pay Hengrui up to $950 million, including a $600 million upfront payment, a $175 million first anniversary payment, and a second contingent anniversary payment of $175 million in 2028. The potential total value of the agreement is up to approximately $15.2 billion, including the exercise of available options for the joint discovery programs and the achievement of applicable development, regulatory, and commercial milestones for all programs. In addition, Hengrui is eligible to receive tiered royalties on net sales of products commercialized outside the Hengrui Territory.

The transaction is subject to review under the Hart‑Scott‑Rodino Antitrust Improvements Act and other customary closing conditions. The parties expect that the agreement will close in the third quarter of 2026.

About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

Bristol Myers Squibb Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the strategic collaboration and license agreements with Hengrui Pharma.  All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our actual future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that the expected benefits of, and opportunities related to, the agreement may not be realized by Bristol Myers Squibb or may take longer to realize than anticipated, that Bristol Myers Squibb may fail to discover and develop any commercially successful product candidates through the agreement, and that assets or product candidates may not achieve their primary study endpoints or receive regulatory approval for the indications described in this release in the currently anticipated timeline or at all and, if approved, whether such product candidate treatment or combination treatment for such indications described in this release will be commercially successful.

No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

About Hengrui Pharma: Innovation to Benefit Patients Worldwide
Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.

Hengrui Pharma Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that reflect Hengrui Pharma's beliefs or expectations about the future or future events as of the respective dates indicated therein ("forward-looking statements"). These forward-looking statements are based on a number of assumptions about Hengrui Pharma's operations, its future development plans, market (financial and otherwise) conditions and growth prospects, and are subject to significant risks, uncertainties and other factors beyond Hengrui Pharma's control, and accordingly, actual results may differ materially from those contemplated by these forward-looking statements. No reliance should be placed on such statements, which reflect the view of the management of Hengrui Pharma as at the date of this press release. Hengrui Pharma does not undertake any obligation to update these forward-looking statements for events/or circumstances that occur subsequent to such dates.

深圳2026年5月12日 /美通社/ -- 近日，全球領先的AI+機器人藥物研發平台晶泰科技（2228.HK）聯合長江生命科技（CK Life Sciences）全資子公司順譜醫藥科技（Sequencio Therapeutics），在美國癌症研究協會（AACR）年會上正式發佈了雙方在AI癌症疫苗平台研發中取得的最新臨床前成果。依托晶泰科技自主研發的PepiX™ AI多肽藥物開發平台，研究團隊針對極具挑戰的廣譜抗癌靶點p53成功優化出新抗原肽段，在親和力、免疫原性、應答持久度方面均展現出優越的實驗數據，取得了該領域具有突破性的進展，為癌症疫苗的後續開發奠定了堅實基礎。這一進展不僅標誌著晶泰科技的AI多肽藥物研發平台在攻堅「難成藥」靶點上取得了實質性成果，更意味著雙方共同開發的AI癌症疫苗平台正穩步跨越早期發現階段。雙方將繼續緊密合作，加速平台成果轉化為具備高臨床潛力的前沿管線。

攻克「抑癌之王」：AI破解p53靶點的長期難題

在腫瘤免疫治療領域，p53作為人類腫瘤中突變頻率最高的抑癌基因，相關突變存在於全球近半數的癌症患者中，覆蓋肺癌、乳腺癌、結直腸癌等多個高發癌種，孕育著巨大的未滿足臨床需求與百億級市場藍海。多肽疫苗憑借其高靶向性、安全性與成本優勢，有望精準引導免疫系統識別並摧毀腫瘤細胞，最大限度減少對健康組織的損傷，並激發持久的T細胞免疫記憶，從根本上防範腫瘤復發。然而，p53新抗原長期以來因免疫原性偏弱、且人類白細胞抗原（HLA）結合譜系狹窄，成藥難度極大，一直被視為傳統研發手段難以摘取的「高懸果實」。

面對這一挑戰，晶泰科技憑借PepiX™平台千萬量級的高質量數據，成功構建了行業領先的深度學習預測模型，並應用於p53新抗原肽的快速預測、序列優化及免疫原性提升。平台顯著提高了對主流MHC-I等位基因的多肽呈遞預測成功率，且AI設計的抗原表位在小鼠模型中展現出強效的T細胞激活能力，經篩選活化的T細胞對腫瘤細胞的殺傷效率超過50%。實驗數據證實，經PepiX™優化改造的肽段能夠與HLA多個主流亞型形成高親和力的穩定結合，並在人源化HLA模型中顯著增強了免疫原性。臨床前細胞免疫原性篩查進一步表明，相較於原始母本肽段，AI設計的修飾肽段可誘導產生更為優異且持久的CD8+ T細胞免疫應答。這些優化後的新表位展現出更出色的交叉反應性與抗腫瘤潛力，為p53驅動型癌症免疫治療的臨床開發奠定了堅實的基礎。

共享百億藍海：AI癌症疫苗平台的商業化加速

隨著生物技術的進步，腫瘤疫苗正處於快速發展的關鍵節點。根據Grand View Research預測，全球癌症疫苗市場將從2025年的99億美元增長至2033年的233億美元，年複合增長率達11.3%。瞄準這一藍海，晶泰科技與長江生命科技於2022年攜手啟動AI癌症疫苗平台合作。2026 年 3 月，長江生命科技宣佈成立公司全資附屬公司順譜醫藥，專注推動旗下治療性癌症疫苗組合的發展。此次AACR發佈的積極數據，充分驗證了該AI癌症疫苗平台的行業領先性。未來，順譜醫藥將與晶泰科技繼續緊密合作，全面推進臨床轉化與商業化。這種「前沿AI算法+頂尖產業資源」深度綁定的創新模式，不僅極大地提升了研發成功率與效率，更樹立了深港兩地生物醫藥產業協同發展的新標桿，加速將科學突破轉化為切實的產業回報。

PepiX™：打造多肽藥物創新的底層基礎設施

多肽藥物兼具小分子藥物的組織穿透性與大分子生物藥的高靶向性，市場潛力巨大，是晶泰科技繼小分子與抗體藥物之後，又一實現前沿技術產業化落地與商業驗證的核心AI研發領域。針對多肽半衰期短、細胞穿透性差等傳統研發痛點，晶泰科技自主研發了一體化多肽開發平台PepiX™。該平台整合了精準AI分子設計、自動化合成與高通量濕實驗篩選三大核心能力，形成「干實驗設計+濕實驗驗證」的高效閉環。PepiX™不僅能顯著縮短研發週期，更能快速篩選出pM級高親和力與高穩定性的分子。

目前，PepiX™已成功賦能數十個複雜多肽研發項目，靶點涵蓋酶、激素、膜蛋白及複雜無序蛋白。其核心的AI驅動多肽分子生成技術、「一珠一物」化學組合庫篩選技術及萬億規模的mRNA展示肽庫篩選技術均已獲得國內外客戶的高度認可，構建起高技術壁壘的一體化多肽研發平台。

在RDC核藥領域，公司聯合景嘉航開啟「AI+核藥」新一代多肽載體開發；在代謝疾病領域，攜手甘李藥業加速創新藥發現，實現從技術研發到臨床轉化的全鏈條協作；在口服多肽領域與興微達深度合作，致力於改變自免、代謝領域多肽藥物主要依賴注射的臨床現狀。通過在穿越血腦屏障（BBB）、難成藥IDP靶點等前沿領域的持續深耕，晶泰科技正以持續獲得驗證的交付能力，將PepiX™平台打造為驅動全球新藥創新的底層基礎設施。未來，公司將繼續拓寬多肽成藥的邊界，以前沿科技加速普適性療法的落地，持續為產業創造科學價值與商業回報。

關於順譜醫藥科技有限公司

順譜醫藥科技有限公司（Sequencio Therapeutics Company Limited，「Sequencio」）為長江生命科技集團有限公司全資附屬公司，專注研發能激活患者自身免疫系統對抗癌細胞的治療性疫苗，旨在維持良好安全性前提下，實現持久而穩定的病情緩解，從而應對現有標準療法的關鍵局限。Sequencio 肩負長遠願景——重塑癌症治療模式，從引導短暫性腫瘤縮小，邁向透過免疫系統達致長期可控的緩解。

關於晶泰科技

晶泰科技（「XtalPi Holdings Limited」，股份簡稱：晶泰控股，XTALPI，股票代碼：2228.HK）由三位麻省理工學院的物理學家於 2015 年創立，是一個基於量子物理、以人工智能賦能和機器人驅動的創新型研發平台。公司採用基於量子物理的第一性原理計算、人工智能、高性能雲計算以及可擴展及標準化的機器人自動化相結合的方式，為製藥及材料科學（包括農業技術、能源及新型化學品以及化妝品）等產業的全球和國內公司提供藥物及材料科學研發解決方案及服務。

SHENZHEN, China, May 11, 2026 /PRNewswire/ -- TCL, a leading global technology company, announced its inclusion in Forbes' 2025 list of the World's Top Companies for Women, recognizing its success in building an inclusive culture and championing women in the workplace.

To compile the list, Forbes partnered with market research firm Statista to survey approximately 120,000 women working for multinational corporations in more than 36 countries. Each company's score aggregates survey responses with a "public opinion score" that quantifies women's gender perceptions of different companies, as well as data on women in executive and board positions. The list ranks 400 corporations with a significant global presence across at least two continents.

In addition to career advancement, TCL offers family-friendly benefits such as mother and baby rooms, extended paid maternity leave and childbirth allowances, along with women's healthcare services including cancer screening and psychological counseling.

"Women's empowerment is a core component of TCL's globalization and sustainability strategy, linking our technological innovation with social development," said Wei Xue, Vice President & Chief of the ESG Office at TCL Technology Group Corporation, and Chairperson of TCL Charity Foundation. "Our inclusion on Forbes' list is a tribute to TCL's long-term commitment to empowering women in the workplace and supporting their career development. We are honored to be included and proud of our track record creating opportunity for all people."

TCL operates in more than 160 countries and regions, engaging with local communities and respecting local cultural norms to empower women in the workplace. The company maintains its commitment to diversity and inclusion by assessing Environmental, Social and Governance indicators in its global subsidiaries and using this data to inform its employment policies.

TCL Extends Female Empowerment Mission Beyond the Workplace

Since 2018, TCL has partnered with FIBA, the world's governing body for basketball, to promote female participation in the sport. The company has supported numerous global events and will continue its involvement with the upcoming FIBA Women's World Cup in Germany in September and the 2027 FIBA World Cup in Qatar. 

Through the Huameng Foundation, a philanthropic initiative established by TCL's founders, the company funds female-focused programs that have enabled nearly 1,000 young women from underprivileged families to complete high school and tertiary studies. The Foundation uses technology to advance its charitable causes, supporting community development in China and elsewhere.

In addition, TCL's dynamic and long-running #TCLforHer campaign leverages technology, sports and education to empower young women and nurture their ambitions through a variety of community initiatives. The campaign shares stories of trailblazers who challenge assumptions and tear down boundaries, inspiring women everywhere to boldly defy stereotypes and fulfill their potential. 

#TCLforHer has received numerous international marketing honors for its storytelling prowess. In January 2025, it won a prestigious Silver Telly Award—a major prize in the global documentary and TV brand film sector—for its 2024 marketing campaign, which centers around two brand films produced by a predominantly female team. 

TCL's inclusion on the Forbes list of the World's Top Companies for Women marks an important milestone, affirming the company's leadership in female empowerment and commitment to breaking the glass ceiling for women worldwide.

About TCL

Founded in 1981, TCL—short for "The Creative Life"—embodies creativity in every aspect of life. As a leading technology brand, TCL is dedicated to delivering innovative solutions—including TVs, smartphones, audio products, smart home devices, display technologies, and clean energy—that enhance customer experiences through two independent entities—TCL Industries and TCL Technology.

With 47 R&D centers and 40 manufacturing bases globally, TCL operates in over 160 countries and regions, cementing its position as a globally competitive smart technology brand. To further inspire greatness, TCL has become an official Worldwide Olympic and Paralympic Partner in the Home Audiovisual Equipment and Home Appliances category.

Taiwan bourse last quoted at 41,917 this morning (11th), up 313 points or about 0.75%. Global chip foundry leader TSMC (2330.TT) bucked the trend, sagging 1.5% to TWD2,255.

Apple Inc. (AAPL.US) and Intel Corporation (INTC.US) reached a preliminary agreement under which Intel will manufacture certain chips used to power Apple devices, the Wall Street Journal cited informed sources over the weekend as saying.

The two companies reportedly engaged in intensive negotiations for more than a year and finalized a formal agreement in recent months.

Major Asia-Pacific chip stocks thrived broadly this morning. SMIC (00981.HK) and HUA HONG SEMI (01347.HK) each spiked about 5%. In South Korea, Samsung Electronics (005930.KS) and SK Hynix (000660.KS) surged 5.7% and 11.2%, respectively, both notching record highs. In Japan, Kioxia (285A.JP) rallied 7.6% to a new high. MediaTek (2454.TW) in Taiwan also jumped up 8.8% to a record high.
~

AASTOCKS Financial News
Website: www.aastocks.com

The robotics sector picked up sharply, China Merchants Securities International (CMSI) wrote in a report. After the May Day holiday, robotics-related stocks in Hong Kong and A-shares markets have turned more vibrant, with share prices charting notable gains.

The broker attributed this to three factors. First, Tesla, Inc. (TSLA.US) was expected to start mass production of its robots in July or August, while supply chain order information is typically released one to two months in advance, giving rise to an early recovery in sector sentiment. Second, after a marked correction since February that formed a bottom range, the robotics sector has once again attracted capital primarily focused on AI industry chain investments. Third, some robotics supply chain companies have traditional core businesses in the automotive industry. Following the release of 1Q results, potential negative factors have been largely digested, shifting market focus back to individual companies growth prospects.

CMSI highlighted key companies to watch. 1) For complete machine manufacturers it recommended focusing on humanoid robot leader UBTECH ROBOTICS (09880.HK), its top pick in the robotics industry chain, as humanoid robot commercial applications are landing the fastest and the company raised its delivery guidance after its annual results. It also named DOBOT (02432.HK), which is a leader in collaborative robots, driven by both industrial and commercial segments, and is expanding rapidly into humanoid robotics. In vertical robotics, GEEKPLUS-W (02590.HK), a leader in warehouse robotics, is also worth attention. 2) For supply chain, its top pick is MINTH GROUP (00425.HK), whose progress in robotics, AI liquid cooling and the low-altitude economy beat expectations. Investors should watch for potential major breakthroughs in the AIDC field. The company's fuel cell system components, including SOFC and PEMFC, achieved order breakthroughs in domestic and overseas markets. SANHUA (02050.HK), a core supplier in the Tesla industry chain, is also highlighted. 3) For broader robotics plays, the broker expected that market interest will spread to the broader robotics segment in the later stage of the rally, with growing attention on HORIZONROBOT-W (09660.HK), HESAI-W (02525.HK) and ROBOSENSE (02498.HK).
~

AASTOCKS Financial News
Website: www.aastocks.com

YOFC's 2025 ESG and Sustainability Report shows the optical fiber giant reducing emissions as technological innovation and smarter manufacturing drive measurable gains.

WUHAN, China, May 11, 2026 /PRNewswire/ -- Yangtze Optical Fibre and Cable Joint Stock Limited Company (YOFC) reduced greenhouse gas emissions intensity by 13.12% year on year and cut total carbon emissions by 86,333 tonnes in 2025. YOFC monitors carbon performance via its self-developed SmartCarbon platform. The platform obtained third-party verification from Bureau Veritas in 2025 and enables granular carbon data tracking at both organizational and product levels.

The results, disclosed in the company's 2025 ESG and Sustainability Report published last week, show a 4.54% reduction in energy consumption intensity, a 28.54% drop in water consumption intensity, and total green electricity consumption of 159,279 MWh. All environmental improvements came alongside YOFC's steady global business expansion, with no compromise to production capacity or global supply capacity.

The sustainability progress comes as YOFC continues to expand its global footprint, having held top-ranking market share in optical preforms, optical fiber, and optical cable for 10 consecutive years across more than 100 countries and regions with nine overseas production facilities.

"In the era of artificial intelligence, optical communication infrastructure is becoming a key foundation of the digital economy. Building that infrastructure sustainably is a strategic core of our long-term development, not a separate obligation," said Dan Zhuang, executive director and president of YOFC.

As a frontrunner in smart, low-carbon manufacturing, YOFC runs a network of digitally smart manufacturing facilities. It deploys automation and digital solutions to boost efficiency, product consistency and low-carbon operations. In 2025, YOFC led or contributed to the formulation of 42 industry standards.

On the product side, YOFC's hollow-core optical fiber achieved a minimum attenuation of 0.04 dB/km, a world-leading figure that will allow network operators to build higher-capacity infrastructure at significantly lower energy cost as AI workloads scale.

Sustainability is embedded throughout YOFC's entire business ecosystem. The Company fully adheres to the ISO 28000 supply chain security management system and has formalized security commitments with all raw material and service suppliers. All suppliers have signed the External Party Code of Conduct and integrity agreements, achieving full compliance at a 100% signing rate. Total annual employee training hours amounted to 238,261, underscoring YOFC's ongoing dedication to talent development and social responsibility as integral pillars of its ESG strategy.

With targets of a 50% reduction in greenhouse gas emissions intensity by 2028 compared with 2021 levels and carbon neutrality by 2055, technological innovation and global expansion will remain central to YOFC's green transformation.

"We will continue to advance our green and low-carbon transition, deepen our global presence, and work with industry partners to build a connectivity ecosystem that is more efficient, more intelligent, and more durable," Zhuang said.

China Association of Automobile Manufacturers (CAAM) said that the online rumors claiming that new energy vehicle (NEV) makers were summoned and investigated over power locking issues are false information.

A relevant official of the CAAM stated that recent widely circulated online claims that eight NEV makers were summoned over power locking issues and three carmakers were formally placed under investigation was not stemmed from official source and were entirely inconsistent with the facts.

In response, XPENG-W (09868.HK), BYD COMPANY (01211.HK), GAC Aion, Zeekr, NIO-SW (09866.HK) and AITO shattered the rumors.

Tesla, Inc. (TSLA.US) and LI AUTO-W (02015.HK) told the media that the rumors of being summoned were untrue. Tesla stated that all of its software updates undergo rigorous testing and filing procedures. XPENG-W said that certain social media accounts maliciously hyped the issue through AI applications and included the company on the list, wreaking severe damage to its brand and reputation. After verification, the company has not been summoned recently nor placed under investigation, and it will pursue legal responsibility in accordance with the law.

BYD COMPANY's anti-fraud office issued a statement noting that false online rumors regarding BYD COMPANY being summoned and investigated were deliberately misleading the public and disrupting the online opinion environment. The company has collected evidence and will pursue legal responsibility against relevant parties in accordance with the law.

GAC Aion's legal department also clarified that the company has never been summoned by relevant authorities over the matters mentioned in the false information, nor has it been included on any investigation list. It will pursue legal responsibility against those spreading rumors in accordance with the law.
~

AASTOCKS Financial News
Website: www.aastocks.com

CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱^®) was accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. The application is for sac-TMT in combination with MSD's^[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA^®[2]) as first‑line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have PD-L1 tumor proportion score (TPS) ≥1% and are EGFR-negative and ALK-negative. This acceptance is based on the positive results from the OptiTROP-Lung05 registrational Phase III study, and the application is the fifth indication application for sac-TMT that has been accepted by the NMPA.

The OptiTROP-Lung05 is a randomized, open-label, multicenter, Phase III clinical study that evaluates the efficacy and safety profile of sac-TMT in combination with pembrolizumab versus pembrolizumab monotherapy as first-line treatment for PD-L1-positive locally advanced or metastatic NSCLC. At a pre-specified interim analysis, the study has met its primary endpoint of progression-free survival (PFS) and demonstrated a statistically significant and clinically meaningful improvement as concluded by the Independent Data Monitoring Committee (IDMC). A positive trend in overall survival (OS) was also observed. Notably, the OptiTROP-Lung05 study is the first Phase III study of an immunotherapy and ADC combination to meet its primary endpoint in first-line NSCLC treatment. The study has been selected for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract number #8506, Lung Cancer –Non-Small Cell Metastatic).

Previously, sac-TMT in combination with intravenous and subcutaneous pembrolizumab for the first-line treatment of patients with locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and ALK-negative was granted Breakthrough Therapy Designation (BTD) by the NMPA. On April 9, 2026, the CDE's official website announced that the Application has entered the priority review and approval process. This marks the fifth sac-TMT indication to enter the CDE's priority review and approval process. Through this process, the review time will be significantly shortened, potentially expediting its approval pathways.

Dr. Michael Ge, CEO of Kelun-Biotech said, "We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA^® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit in OS. This achievement holds significant importance for improving current treatment regimens for lung cancer. We will continue to collaborate with our partners to advance the clinical development and commercialization of sac-TMT, to help more patients with lung cancer and enhance their survival outcomes."

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China's National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA.

Sac-TMT is the world's first TROP2 ADC drug approved for marketing in lung cancer. A new indication application for sac-TMT in combination with pembrolizumab (KEYTRUDA^®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and ALK-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD has initiated 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.